Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Risk factors for mortality in AIDS-associated Kaposi sarcoma in a primary care antiretroviral treatment program in Malawi.

Chu K, Misinde D, Massaquoi M, Pasulani O, Mwagomba B, Ford N, Zachariah R.

Int Health. 2010 Jun;2(2):99-102. doi: 10.1016/j.inhe.2010.04.001.

PMID:
24037469
2.

Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi.

Herce ME, Kalanga N, Wroe EB, Keck JW, Chingoli F, Tengatenga L, Gopal S, Phiri A, Mailosi B, Bazile J, Beste JA, Elmore SN, Crocker JT, Rigodon J.

J Int AIDS Soc. 2015 May 29;18:19929. doi: 10.7448/IAS.18.1.19929. eCollection 2015.

3.

AIDS-associated Kaposi sarcoma: outcomes after initiation of antiretroviral therapy at a university-affiliated hospital in urban Zimbabwe.

Nelson BC, Borok MZ, Mhlanga TO, Makadzange AT, Campbell TB.

Int J Infect Dis. 2013 Oct;17(10):e902-6. doi: 10.1016/j.ijid.2013.04.011. Epub 2013 Jul 1.

4.

Characteristics and survival for HIV-associated multicentric Castleman disease in Malawi.

Gopal S, Liomba NG, Montgomery ND, Moses A, Kaimila B, Nyasosela R, Chikasema M, Dhungel BM, Kampani C, Sanders MK, Krysiak R, Dittmer DP, Fedoriw Y.

J Int AIDS Soc. 2015 Aug 3;18:20122. doi: 10.7448/IAS.18.1.20122. eCollection 2015.

5.

Outcomes of patients with Kaposi's sarcoma who start antiretroviral therapy under routine programme conditions in Malawi.

Makombe SD, Harries AD, Yu JK, Hochgesang M, Mhango E, Weigel R, Pasulani O, Fitzgerald M, Schouten EJ, Libamba E.

Trop Doct. 2008 Jan;38(1):5-7. doi: 10.1258/td.2007.060023.

PMID:
18302849
6.

Treatment outcomes of AIDS-associated Kaposi's sarcoma under a routine antiretroviral therapy program in Lilongwe, Malawi: bleomycin/vincristine compared to vincristine monotherapy.

Mwafongo AA, Rosenberg NE, Ng'ambi W, Werner AB, Garneau WM, Gumulira J, Phiri S, Hosseinipour MC.

PLoS One. 2014 Mar 14;9(3):e91020. doi: 10.1371/journal.pone.0091020. eCollection 2014.

7.

Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe.

Borok M, Fiorillo S, Gudza I, Putnam B, Ndemera B, White IE, Gwanzura L, Schooley RT, Campbell TB.

Clin Infect Dis. 2010 Aug 1;51(3):342-9. doi: 10.1086/654800.

PMID:
20572760
8.

Chemotherapy for AIDS-related and endemic African Kaposi's sarcoma in southern Africa.

Stein ME, Lachter J, Spencer D, Bezwoda WR.

Int J Dermatol. 1995 Oct;34(10):729-32.

PMID:
8537166
9.

Kaposi sarcoma: no longer an AIDS-defining illness? A retrospective study of Kaposi sarcoma cases with CD4 counts above 300/mm³ at presentation.

Daly ML, Fogo A, McDonald C, Morris-Jones R.

Clin Exp Dermatol. 2014 Jan;39(1):7-12. doi: 10.1111/ced.12163. Epub 2013 May 21.

PMID:
23691969
11.

Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.

Dupont C, Vasseur E, Beauchet A, Aegerter P, Berthé H, de Truchis P, Zucman D, Rouveix E, Saiag P.

AIDS. 2000 May 26;14(8):987-93.

PMID:
10853980
12.

Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma.

Tulpule A, Groopman J, Saville MW, Harrington W Jr, Friedman-Kien A, Espina BM, Garces C, Mantelle L, Mettinger K, Scadden DT, Gill PS.

Cancer. 2002 Jul 1;95(1):147-54.

13.

Oral HIV-associated Kaposi sarcoma.

Pantanowitz L, Khammissa RA, Lemmer J, Feller L.

J Oral Pathol Med. 2013 Mar;42(3):201-7. doi: 10.1111/j.1600-0714.2012.01180.x. Epub 2012 Jun 5. Review.

PMID:
22672182
14.

Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years. AIDS in Europe Study Group.

Hermans P, Lundgren J, Sommereijns B, Pedersen C, Vella S, Katlama C, Lüthy R, Pinching AJ, Gerstoft J, Pehrson P, Clumeck N.

AIDS. 1996 Jul;10(8):911-7.

PMID:
8828749
15.

AIDS-related Kaposi's sarcoma patients with visceral manifestations. Response to human chorionic gonadotropin preparations.

Hermans P, Clumeck N, Picard O, van Vooren JP, Duriez P, Zucman D, Bryant JL, Gill P, Lunardi-Iskandar Y, Gallo RC.

J Hum Virol. 1998 Jan-Feb;1(2):82-9.

PMID:
10195236
16.

HIV-associated Kaposi sarcoma in African children.

Feller L, Khammissa RA, Gugushe TS, Chikte UM, Wood NH, Meyerov R, Lemmer J.

SADJ. 2010 Feb;65(1):20-2. Review.

PMID:
20411798
17.

The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study.

Mocroft A, Kirk O, Clumeck N, Gargalianos-Kakolyris P, Trocha H, Chentsova N, Antunes F, Stellbrink HJ, Phillips AN, Lundgren JD.

Cancer. 2004 Jun 15;100(12):2644-54.

18.

Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection.

Achenbach CJ, Harrington RD, Dhanireddy S, Crane HM, Casper C, Kitahata MM.

Clin Infect Dis. 2012 Feb 1;54(3):424-33. doi: 10.1093/cid/cir802. Epub 2011 Nov 17.

19.
20.

AIDS-associated Kaposi's sarcoma is more aggressive in women: a study of 54 patients.

Nasti G, Serraino D, Ridolfo A, Antinori A, Rizzardini G, Zeroli C, Nigro L, Tavio M, Vaccher E, Tirelli U.

J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 1;20(4):337-41.

PMID:
10096577

Supplemental Content

Support Center